- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT01941849
Phase I Trial of Vandetanib Combined With 131I-mIBG to Treat Patients With Advanced Phaeochromocytoma and Paraganglioma (VIBRaNT)
A Phase I Trial of Vandetanib Combined With 131I-mIBG Radiotherapy in Patients With Neuroendocrine Tumours, Advanced Phaeochromocytoma and Paraganglioma
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Detaljert beskrivelse
VIBRaNT is a registered phase I trial in patients with locally advanced or metastatic phaeochromocytoma or paraganglioma, not amenable to surgical resection.
Patients will receive vandetanib (an inhibitor of VEGF, EGFR and RET tyrosine kinase) in combination with standard radiation therapy Iodine-131 labelled Meta-iodobenzylguanidine (131I-mIBG).
Vandetanib and 131I-mIBG will be given in 12-weekly cycles: 131I-miBG will be given on day 1 of each cycle and vandetanib will started on day 1 of each cycle and continue to be taken once every day. The phase I trial aims to determine with recommended phase II dose of vandetanib (either 100, 200 or 300 mg once daily) - the dose of vandetanib that patients will receive will depend on the dose under investigation at the time of patient registration.
The vandetanib dose will be determined by the Modified Continual Reassessment Method (mCRM) - a toxicity model which described the probability of a toxicity occurring at each dose level, which is based on clinical judgement and any available toxicity data.
Studietype
Fase
- Fase 1
Kontakter og plasseringer
Studiesteder
-
-
-
London, Storbritannia
- University College London Hospitals NHS Foundation Trust
-
London, Storbritannia
- Guy's and St Thomas' NHS Foundation Trust
-
London, Storbritannia
- The Christie NHS Foundation Trust
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Histopathological/cytological diagnosis of advanced phaeo/PG defined as patients with local or metastatic disease not amenable to surgical resection, or R1 resection post original surgical debulking
- Positive 123I-mIBG diagnostic scan
- Stable blood pressure (<140/90mmHg), if appropriate, on anti-hypertensive therapy
- No previous systemic chemotherapy within 3 months prior to registration
- No previous mIBG therapy within 12 months prior to registration (previous cumulative activity must not exceed 15 GBq)
- Measurable disease (RECIST v1.1)
- WHO performance status 0 or 1
- Age ≥ 18
- Estimated life expectancy > 3 months.
- Adequate bone marrow function: Haemoglobin ≥ 100 g/L, White Blood Cell ≥ 3.0 x 10^9/L, Absolute neutrophil ≥ 1.5 x 10^9/L, Platelet ≥ 100 x 10^9/L
- Adequate liver function: Total bilirubin ≤1.5 x Upper Limit of Normal (ULN); ALT/AST and ALP≤ 2.5 x ULN or ≤ 5 x ULN if related to liver metastases
- Adequate renal function: Serum urea and creatinine < 1.5x ULN AND Calculated creatinine clearance (GFR) ≥50 mL/min. If the calculated GFR is below 50, isotope clearance test is required to confirm GFR ≥50 mL/min
- Electrolytes: Potassium ≥ 4.0 mmol/L and ≤ 5.5 mmol/L, Magnesium ≥ Lower Limit of Normal and ≤ 1.23 mmol/L, Corrected calcium within institution normal range
- Negative pregnancy test for women of child-bearing potential AND be using adequate barrier contraception, which must be continued for 12 months after completion of treatment (male patients must also agree to use barrier contraception during the trial and for 12 months after completion of treatment)
- Able to swallow oral medication
- Capable of giving written informed consent
Exclusion Criteria:
- Patients undergoing current treatment with curative intent
- Previous or current malignancies of other histological types within the last 5 years (exceptions listed in the trial protocol)
- Any prior exposure to VEGF, EGFR or RET inhibitors or history of hypersensitivity to vandetanib or any excipient agents
- Evidence of severe or uncontrolled systemic diseases or laboratory finding that in the view of the investigator makes it undesirable for the patient to participate in the trial
- Evidence of active uncontrolled infection (patients on antibiotics are eligible)
- Chronic gastrointestinal disease (e.g. Inflammatory Bowel Disease) or significant bowel resection that would preclude adequate absorption
Cardiovascular exclusion criteria (complete list provided in the trial protocol):
- Significant cardiac event (myocardial infarction), New York Heart Association Class II or above, within 12 weeks before registration, or presence of cardiac disease that in the opinion of the investigator increased the risk of ventricular arrhythmia
- Prior or current cardiomyopathy
- Baseline LVEF < 40% as measured by ECHO/MUGA
- Atrial fibrillation with heart rate >100 bpm
- Unstable ischaemic heart disease (myocardial infarction within 6 months prior to starting treatment, or angina requiring use of nitrates more than once weekly)
- History of arrhythmia that was symptomatic or required treatment
- QTcB prolongation >480 ms at baseline
- QT prolongation with other medications that required discontinuation of that medication
- Any psychiatric or other disorder likely to impact on informed consent or ability to manage isolation
- Major surgery within 28 days prior to registration
- Brain metastases or spinal cord compression, unless treated at least four weeks before the first dose and stable without steroid treatment for 10 days
- Any concomitant medications that may affect QTc, induce or inhibit CYP3A4 function (with the exception of somatostatin or somatostatin analogue) and/or prohibited medications
- Women who are pregnant or lactating
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: N/A
- Intervensjonsmodell: Enkeltgruppeoppdrag
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
---|---|
Eksperimentell: Vandetanib + 131I-mIBG
Vandetanib (100, 200 or 300 mg once daily) in combination with 131I-mIBG radiation therapy (activity to be prescribed to deliver whole body absorbed dose of 0.5 Gy) on day 1 of each 12-weekly cycle. Patients will receive up to 4 cycles of vandetanib in combination with 131I-mIBG. |
100 mg, 200 mg or 300 mg taken once a day during each 12-weekly cycle
Andre navn:
Activity will be prescribed to deliver whole body absorbed dose of 0.5 Gy (+/-10%)
Andre navn:
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Occurrence of Dose Limiting Toxicity
Tidsramme: From start of cycle 1 to end of cycle 1 (each cycle = 12 weeks)
|
Detailed adverse event monitoring will be conducted according to CTCAE v4.03.
Dose Limiting Toxicity (DLT) is defined as any adverse event or laboratory abnormality detailed in the trial protocol, that is considered to be highly probable or probable trial treatment related and commencing anytime during the DLT evaluation period (from start of cycle 1 to cycle 1 week 12).
Adverse Events include: Haematological, Clinical Chemistry, Cardiovascular, Gastrointestinal, Skin.
|
From start of cycle 1 to end of cycle 1 (each cycle = 12 weeks)
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Objective response
Tidsramme: Determined using imaging scans performed at baseline (registration), then every 3 months after start of treatment until disease progression up to 3 years from date of registration
|
Response will be assessed according to RECIST v1.1.
Confirmation of complete or partial response is not required.
Stable disease will be considered the best response only is a second assessment has been carried out which confirmed stable disease at least 4 weeks after trial entry.
Assessment will be determined using CT scans and 123I-mIBG scans performed at baseline, then every 3 months after start of treatment until disease progression (up to 3 years from registration)
|
Determined using imaging scans performed at baseline (registration), then every 3 months after start of treatment until disease progression up to 3 years from date of registration
|
Occurrence and Severity of Adverse Events
Tidsramme: From date of registration until 30 days after completion of trial treatment (vandetanib and/or 131I-mIBG)
|
Will include all grade 1-5 adverse events.
|
From date of registration until 30 days after completion of trial treatment (vandetanib and/or 131I-mIBG)
|
Progression Free Survival
Tidsramme: From date of registration to date of documented disease progression or death from any cause, whichever comes first, assessed up to 3 years from date of registration
|
Progression-free survival will be calculated from the date of trial entry to the date of documented disease progression, or death from any cause.
Where progression is suspected and subsequently confirmed by scans, the date of documented suspected progression will be used.
|
From date of registration to date of documented disease progression or death from any cause, whichever comes first, assessed up to 3 years from date of registration
|
Samarbeidspartnere og etterforskere
Sponsor
Etterforskere
- Hovedetterforsker: Christina Thirlwell, University College London (UCL) Cancer Institute
Studierekorddatoer
Studer hoveddatoer
Studiestart
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Anslag)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Anslag)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- UCL/12/0499
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Paragangliom
-
Peking Union Medical College HospitalRekrutteringEffekten og sikkerheten til anlotinib hos pasienter med metastatisk feokromocytom eller paragangliomParagangliom, ekstra binyre | Ondartet binyre feokromocytom | Ondartet paragangliom | Feokromocytom, metastatisk | Paragangliom, ondartetKina
-
National Cancer Institute (NCI)RekrutteringMetastatisk binyrefeokromocytom | Metastatisk paragangliom | Feokromocytom i binyrene som ikke kan gjenopptas | Uoperabelt paragangliom | Avansert binyrefeokromocytom | Avansert paragangliom | Stadium III binyrefeokromocytom og sympatisk paragangliom AJCC v8 | Stadium IV binyre feokromocytom og sympatisk...Forente stater
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Aktiv, ikke rekrutterendeMetastatisk binyrefeokromocytom | Lokalt avansert paragangliom | Metastatisk paragangliom | Feokromocytom i binyrene som ikke kan gjenopptas | Uoperabelt paragangliom | Regional binyrefeokromocytomForente stater
-
Abramson Cancer Center of the University of PennsylvaniaFullførtUoperabelt paragangliom | Tilbakevendende feokromocytom | Avansert metastatisk paragangliom | Avansert metastatisk feokromocytom | Tilbakevendende paragangliom | Ikke-opererbart feokromocytomForente stater
-
National Cancer Institute (NCI)AvsluttetParagangliom | Metastatisk binyrefeokromocytom | Tilbakevendende binyrefeokromocytom | Ekstra-binyreparagangliomForente stater, Singapore, Hong Kong
-
Seoul National University HospitalFullførtFeokromocytom | Ekstra binyreparagangliom | Ikke-fungerende karsinoidKorea, Republikken
-
Pamukkale UniversityFullførtHode og nakke paragangliomTyrkia
-
Assistance Publique - Hôpitaux de ParisSociety for EndocrinologyRekrutteringParagangliom av hode og nakkeFrankrike
-
Nanjing First Hospital, Nanjing Medical UniversityRekrutteringAvansert eller metastatisk paragangliom/feokromocytomKina
-
Peking Union Medical College HospitalRekrutteringFeokromocytom, metastatisk | Paragangliom, ondartet | Feokromocytom ondartetKina
Kliniske studier på Vandetanib
-
National Cancer Institute (NCI)FullførtNyrekreft | Von Hippel LindauForente stater
-
Genzyme, a Sanofi CompanyFullførtKreft i skjoldbruskkjertelenForente stater, Frankrike
-
National Cancer Institute (NCI)FullførtMultippel endokrin neoplasi type 2A | Multippel endokrin neoplasi type 2B | Medullært skjoldbruskkarsinomForente stater
-
Samsung Medical CenterAstraZenecaFullført
-
Genzyme, a Sanofi CompanyAktiv, ikke rekrutterendeKreft i skjoldbruskkjertelenForente stater, Italia, Polen, Den russiske føderasjonen, Storbritannia, Nederland, Israel, Tsjekkia, India
-
Genzyme, a Sanofi CompanyFullført
-
M.D. Anderson Cancer CenterUnited States Department of Defense; AstraZenecaFullført
-
St. Jude Children's Research HospitalFullførtSvulster i hjernen og sentralnervesystemetForente stater
-
Genzyme, a Sanofi CompanyFullførtNeoplasmer i skjoldbruskkjertelenSverige, Frankrike, Spania, Norge, Belgia, Danmark, Sveits